Drugs / GHB16L2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01369862 | Jan → Aug 2011 | influenza | AVIR Green Hills Biotechnology AG | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GHB16L2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01369862 ↗ |
| Route | Intranasal | “single intranasal dose” PMID 24183981 ↗ Oct 2013 |